We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $113M
1-Year Est. Return 245.92%
This Fund
S&P 500
This Quarter Est. Return
+5.28%
1 Year Est. Return
+245.92%
3 Year Est. Return
+826.04%
5 Year Est. Return
+770.7%
10 Year Est. Return
–
AUM
$111M
AUM Growth
-$5.7M
Cap. Flow
-$3.13M
Cap. Flow %
-2.82%
Top 10 Hldgs %
64.59%
Holding
34
New
4
Increased
10
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$10.4M
2
VRNA
Verona Pharma
VRNA
+$8.32M
3
TECX
Tectonic Therapeutic
TECX
+$4.31M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$3.16M
5
GERN icon
Geron
GERN
+$2.39M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$12.3M
2
ALMS
Alumis Inc
ALMS
+$3.5M
3
JSPR icon
Jasper Therapeutics
JSPR
+$2.62M
4
EYPT icon
EyePoint Inc
EYPT
+$2.59M
5
ETNB
89bio
ETNB
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 92.76%
2 Miscellaneous 7.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$12.4M 11.18%
281,139
+226,447
+414% +$10.4M
VRNA
2
DELISTED
Verona Pharma
VRNA
$8.83M 7.96%
+139,067
New +$8.32M
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
$8.61M 7.76%
120,449
+32,820
+37% +$1.6M
AXSM icon
4
Axsome Therapeutics
AXSM
$10.8B
$8.41M 7.58%
72,113
+5,452
+8% +$621K
TARS icon
5
Tarsus Pharmaceuticals
TARS
$3.98B
$6.57M 5.92%
127,932
-45,212
-26% -$2.23M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$6.57M 5.92%
74,192
+18,300
+33% +$1.79M
INSM icon
7
Insmed
INSM
$27.6B
$6.49M 5.85%
85,110
-29,250
-26% -$2.24M
AXSM icon
8
CALL
Axsome Therapeutics
AXSM
$10.8B
$5.83M 5.26%
+50,000
New +$5.7M
TRVI icon
9
Trevi Therapeutics
TRVI
$2.46B
$4.32M 3.89%
686,219
-95,270
-12% -$454K
PRAX icon
10
Praxis Precision Medicines
PRAX
$9.82B
$3.62M 3.26%
95,582
+50,600
+112% +$3.16M
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
$3.5M 3.15%
243,086
-1,452
-0.6% -$23.8K
ELVN icon
12
Enliven Therapeutics
ELVN
$4.35B
$3.34M 3.01%
169,774
+28,064
+20% +$604K
MRUS
13
DELISTED
Merus
MRUS
$3.28M 2.96%
77,896
-38,900
-33% -$1.7M
GERN icon
14
Geron
GERN
$1.01B
$3.27M 2.95%
2,056,637
+981,813
+91% +$2.39M
CGON icon
15
CG Oncology
CGON
$6.62B
$3.24M 2.92%
132,298
-41,750
-24% -$1.17M
ATYR
16
aTyr Pharma
ATYR
$48.8M
$2.35M 2.12%
777,020
+77,290
+11% +$282K
TECX
17
Tectonic Therapeutic
TECX
$601M
$2.34M 2.11%
+132,222
New +$4.31M
XENE icon
18
Xenon Pharmaceuticals
XENE
$5.79B
$2.34M 2.11%
69,603
-59,688
-46% -$2.27M
DFTX
19
Definium Therapeutics
DFTX
$5.12B
$2.28M 2.06%
390,143
+59,868
+18% +$429K
EWTX icon
20
Edgewise Therapeutics
EWTX
$4.68B
$2.26M 2.04%
102,650
+19,474
+23% +$511K
EWTX icon
21
CALL
Edgewise Therapeutics
EWTX
$4.68B
$2.2M 1.98%
+100,000
New +$2.62M
JANX icon
22
Janux Therapeutics
JANX
$1.24B
$2.19M 1.98%
81,292
-9,000
-10% -$339K
DNTH icon
23
Dianthus Therapeutics
DNTH
$6.05B
$1.46M 1.32%
80,584
-25,850
-24% -$570K
WHWK
24
Whitehawk Therapeutics
WHWK
$262M
$1.46M 1.31%
817,939
– –
KRRO icon
25
Korro Bio
KRRO
$180M
$1.04M 0.94%
59,723
-10,955
-15% -$325K
1
2

Similar funds

IA
Invested Advisors State College, Pennsylvania $113M AUM 23.72% 1-Year Est. Return
CPA
Clear Point Advisors Melville, New York $113M AUM 15% 1-Year Est. Return
MBC
Michael Brady & Co Westlake, Ohio $113M AUM
OCM
Objective Capital Management Pepper Pike, Ohio $113M AUM 22.81% 1-Year Est. Return
AWA
Ark Wealth Advisors Yorba Linda, California $113M AUM
TWS
Thomas W. Smith $113M AUM
OFP
OFC Financial Planning Short Hills, New Jersey $113M AUM 26.89% 1-Year Est. Return
IIM
IFC & Insurance Marketing Auburn, California $114M AUM

Ally Bridge Group's Q1 2025 Portfolio in Review

As of Q1 2025, Ally Bridge Group held 34 positions worth $111M, down 4.9% from $117M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Ally Bridge Group's Q1 2025 filing shows 4 new, 10 increased, 13 reduced and 6 closed positions. Its largest new stake was Verona Pharma: 139,067 shares worth $8.83M. The largest sale was Intra-Cellular Therapies Inc., an estimated $12.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Ally Bridge Group's largest Q1 2025 buy was Verona Pharma: 139,067 shares worth $8.83M.
  • Ally Bridge Group added most to SpringWorks Therapeutics in Q1 2025, an estimated $10.4M increase.
  • Ally Bridge Group's biggest Q1 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $2.27M.
  • Ally Bridge Group fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $12.3M.
  • Ally Bridge Group's ten largest holdings make up 65% of its $111M portfolio in Q1 2025.
  • Ally Bridge Group opened 4 new positions and closed 6 in Q1 2025.
  • Ally Bridge Group's portfolio value fell 4.9% quarter-over-quarter to $111M.

Based on Ally Bridge Group's 13F filing for Q1 2025, filed 15 May 2025.